Citadel Advisors
SLGC

Citadel Advisors’s SomaLogic, Inc. Class A Common Stock SLGC Stock Holding History

Citadel Advisors’s Portfolio SLGC Stock Details SLGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$253 – 15852
2023
Q4 		$253 Sell
100
-3,300
-97% -$7.68K ﹤0.01% 14075
2023
Q3 		$8.13K Sell
3,400
-3,300
-49% -$7.31K ﹤0.01% 13217
2023
Q2 		$15.5K Sell
6,700
-59,000
-90% -$167K ﹤0.01% 12944
2023
Q1 		$168K Buy
65,700
+6,700
+11% +$19.2K ﹤0.01% 10462
2022
Q4 		$148K Buy
59,000
+38,600
+189% +$108K ﹤0.01% 10628
2022
Q3 		$59K Sell
20,400
-42,600
-68% -$179K ﹤0.01% 11519
2022
Q2 		$285K Sell
63,000
-39,600
-39% -$236K ﹤0.01% 9922
2022
Q1 		$823K Buy
+102,600
New +$905K ﹤0.01% 8154

Citadel Advisors's SLGC Position: Q1 2024 in Review

Citadel Advisors sold out of SomaLogic, Inc. Class A Common Stock (SLGC) in Q1 2024, closing a stake of 50,798 shares — an estimated $129K sold.

Citadel Advisors first reported a position in SLGC in Q3 2021 and held it in 9 quarters. The position peaked at $16.1M in Q1 2022. 0 funds tracked by Wall St. Rank hold SLGC as of Q1 2024.

  • Citadel Advisors reported no remaining SomaLogic, Inc. Class A Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 50,798 SomaLogic, Inc. Class A Common Stock shares in Q1 2024, an estimated $129K.
  • Citadel Advisors first reported a position in SomaLogic, Inc. Class A Common Stock in Q3 2021 and held it in 9 quarters.
  • Citadel Advisors's SomaLogic, Inc. Class A Common Stock position peaked at $16.1M in Q1 2022.
  • 0 funds tracked by Wall St. Rank held SomaLogic, Inc. Class A Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.